Centene raises 2026 outlook after Q2 profit tops $1 billion

Centene Corp. posted second-quarter net income of $1.09 billion, swinging from a year-earlier loss, as the managed-care company's medical costs stabilized and it raised its full-year 2026 outlook above Wall Street expectations.

"Our second quarter results and improved full-year outlook represent meaningful milestones on our path to restoring profitability and increasing shareholder value," Chief Executive Officer Sarah M. London said. "We are excited by the positive momentum we have built and remain focused on our goal of delivering industry-leading health outcomes with an industry-leading cost structure."

The Saint Louis, Missouri-based insurer reported earnings of $2.19 a share for the quarter ended June 30, compared with a loss of $253 million, or 50 cents a share, in the same period last year. Revenue rose 4 percent to $44.4 billion from $42.5 billion, driven by premium yield and growth in its prescription drug plan business, rate increases in marketplace and Medicaid, and risk adjustment revenue transfers.

Centene's health benefits ratio — the percentage of premiums spent on medical claims — fell to 89.6 percent from 93 percent a year earlier, as elevated healthcare costs that weighed on the industry showed signs of easing. The commercial segment HBR came in at 79.2 percent, well below the 90 percent threshold that typically concerns investors. The company attributed the improvement to better pricing, risk transfer reflecting marketplace membership acuity, and progress managing Medicaid medical costs.

Total enrollment fell to about 25.9 million from 28 million a year earlier, driven largely by a drop in marketplace plans sold under the Ambetter brand. Marketplace enrollment declined to 3.5 million from 5.8 million after Congress declined to extend enhanced Affordable Care Act tax credits, causing premiums to double or triple for some customers. Premium and service revenues still rose as higher rates and risk adjustment payments offset the membership decline.

The improved cost structure and profitability trajectory prompted Centene to lift its full-year 2026 earnings guidance above consensus. The company has implemented cost-control measures including companywide worker buyouts disclosed earlier this year. The favorable resolution of programmatic elements for the 2025 benefit year in Medicare and the absence of a premium deficiency reserve for its Medicare Advantage business in 2026 also contributed to the improved outlook.

The results mark a turning point for one of the largest providers of Obamacare and Medicaid health benefits. After several quarters of elevated medical costs that pressured margins across the managed-care sector, Centene's improving HBR suggests the industry may be finding its footing. The company's ability to grow premium revenue while managing a smaller, higher-acuity membership base will be closely watched by investors tracking the broader sector, including UnitedHealth Group Inc. and Humana Inc.

This article is for informational purposes only and does not constitute investment advice.